Microfluidic model of bleeding developed for research | Vaccinated leukemia patients vulnerable to influenza | Pharmacist-led intervention boosts adherence in patients with HIV
February 15, 2018
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Microfluidic model of bleeding developed for research
Emory University School of Medicine scientists have created a miniature model to simulate a mechanical injury to a small blood vessel and track the hemostatic process at the single-cell level. The microfluidics-based system allows researchers to observe the three mechanisms involved in bleeding at work together: blood vessel narrowing, platelet activity and clotting factor activity.
Hemophilia News Today (2/14) 
LinkedIn Twitter Facebook Google+ Email
Science & Health
Vaccinated leukemia patients vulnerable to influenza
Researchers analyzed data for 498 leukemia patients with a median age of 6 for three influenza seasons from 2010 to 2013 and found that rates of influenza and influenza-like illness were the same with and without influenza vaccination. Hand hygiene and additional precautionary measures should be taken for leukemia patients, according to the study in the Journal of Pediatrics.
Healio (free registration)/HemOnc Today (2/14) 
LinkedIn Twitter Facebook Google+ Email
Pharmacist-led intervention boosts adherence in patients with HIV
Including pharmacists in multidisciplinary health care teams improves HIV patients' adherence to antiretroviral therapy, according to a study published in the Journal of Managed Care and Specialty Pharmacy. Viral load decreased to undetectable levels in patients referred to a pharmacist-led ART adherence clinic, and the researchers estimated a 3-to-1 return on investment in avoided medical costs.
Specialty Pharmacy Times (2/12) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Japan's Astellas acquires US stem cell firm for $102.5M
Astellas Pharma will pay $102.5 million upfront to acquire Seattle-based Universal Cells, the firm that developed the Universal Donor Cell technology, which produces cell therapy products that do not need human leukocyte antigen matching. The deal will also let Japan-based Astellas apply the technology to other diseases.
Xconomy (2/14),  Seeking Alpha (free registration) (2/14) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
2 sites added for Trovagene's early-stage leukemia candidate trial
Trovagene added two sites to the Phase Ib/II study evaluating the efficacy of its drug candidate PCM-075 in patients with acute myeloid leukemia.
Reuters (2/13) 
LinkedIn Twitter Facebook Google+ Email
Government & Regulatory
UN's Glasser: More work needed to prevent pandemics
More must be done to prevent pandemic outbreaks of viruses, said Robert Glasser, outgoing head of the United Nations' Office for Disaster Risk Reduction. These new diseases can kill millions of people, he said.
Reuters (2/10) 
LinkedIn Twitter Facebook Google+ Email
Banyan Biomarkers' concussion assay gains FDA approval
Banyan Biomarkers' Brain Trauma Indicator is the first blood test to receive FDA approval to screen for a certain type of brain damage that is usually only detectable with CT scans. The test assesses levels of two proteins, UCH-L1 and GFAP, and it could reduce the need for unnecessary neuroimaging tests and radiation exposure.
STAT (tiered subscription model) (2/14) 
LinkedIn Twitter Facebook Google+ Email
Association News
Redesigned AABB News highlights patient blood management
AABB published the first issue of the newly redesigned AABB News, which focuses on patient blood management. The magazine features articles on how institutions are convincing physicians to embrace PBM using clinical evidence and empowerment strategies and how some champions met the challenges of bringing PBM into community, pediatric and teaching hospital settings. Other articles describe how blood centers responded to Hurricane Harvey and research presented at the 2017 AABB Annual Meeting.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Clinical Nurse Supervisor, Therapeutic Apheresis Service
Learn to conquer your fears. That's the only art we have to learn to master these days.
Friedrich Durrenmatt,
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information